Ftse Mib
34.395,62
0,06%
DAX
18.518,03
-0,44%
S&P 500
5.667,20
0,64%
NASDAQ
18.509,34
0,20%
Bitcoin
64.608,50
-0,38%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biodesix Inc (BDSX) Biodesix Inc (BDSX) Notizie

BDSX

Biodesix (BDSX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BDSX
DataOraFonteTitoloSimboloCompagnia
12/12/202212:00Business WireBiodesix Ranked Top Proteomics Solutions Company by Life Sciences Review MagazineNASDAQ:BDSXBiodesix Inc
01/12/202222:46Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BDSXBiodesix Inc
23/11/202222:31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:BDSXBiodesix Inc
23/11/202222:31Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BDSXBiodesix Inc
22/11/202212:54TipRanksBiodesix (NASDAQ:BDSX) Stock Spikes on String of Insider PurchasesNASDAQ:BDSXBiodesix Inc
22/11/202200:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BDSXBiodesix Inc
21/11/202222:01Business WireBiodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesNASDAQ:BDSXBiodesix Inc
18/11/202222:10Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BDSXBiodesix Inc
17/11/202206:26Business WireBiodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common StockNASDAQ:BDSXBiodesix Inc
16/11/202222:05Business WireBiodesix Announces Proposed Public Offering of Common StockNASDAQ:BDSXBiodesix Inc
16/11/202222:01Business WireBiodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 MillionNASDAQ:BDSXBiodesix Inc
10/11/202215:00Business WireBiodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNASDAQ:BDSXBiodesix Inc
03/11/202211:00Business WireBiodesix Announces Third Quarter 2022 Results and HighlightsNASDAQ:BDSXBiodesix Inc
20/10/202212:00Business WireBiodesix to Report Third Quarter 2022 Financial Results on November 3, 2022NASDAQ:BDSXBiodesix Inc
17/10/202212:00Business WireBiodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing SolutionsNASDAQ:BDSXBiodesix Inc
12/10/202212:00Business WireBiodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening ProgramsNASDAQ:BDSXBiodesix Inc
11/10/202212:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BDSXBiodesix Inc
11/10/202212:00Business Wire Biodesix Announces Preliminary Revenue for Third Quarter 2022NASDAQ:BDSXBiodesix Inc
06/09/202212:00Business WireBiodesix to Participate in Two Upcoming Investor Conferences in SeptemberNASDAQ:BDSXBiodesix Inc
09/08/202212:00Business WireBiodesix Named a Top 100 Healthcare Technology Company of 2022NASDAQ:BDSXBiodesix Inc
04/08/202212:00Business WireBiodesix Announces Second Quarter 2022 Results and HighlightsNASDAQ:BDSXBiodesix Inc
03/08/202212:00Business WireBiodesix to Present at the Canaccord Genuity 42nd Annual Growth ConferenceNASDAQ:BDSXBiodesix Inc
20/07/202212:00Business WireBiodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint InhibitorsNASDAQ:BDSXBiodesix Inc
19/07/202212:00Business WireBiodesix to Report Second Quarter 2022 Financial Results on August 4, 2022NASDAQ:BDSXBiodesix Inc
07/06/202212:00Business WireBiodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule TestNASDAQ:BDSXBiodesix Inc
06/06/202223:26Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BDSXBiodesix Inc
03/06/202212:00Business WireBiodesix Announces Research Agreement with Top US Cancer CenterNASDAQ:BDSXBiodesix Inc
01/06/202212:00Business WireBiodesix to Present at the 42nd Annual William Blair Growth Stock ConferenceNASDAQ:BDSXBiodesix Inc
17/05/202212:00Business WireBiodesix to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:BDSXBiodesix Inc
12/05/202212:00Business WireBiodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to be Presented at ATS 2022 International ConferenceNASDAQ:BDSXBiodesix Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BDSX

La tua Cronologia

LSE
IESE
Ishr Msci Eur
LSE
UB01
Ubsetf E50gba
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network